RNA polymerase III subunit D pseudogene 1Genealiases: []
Q-omics provides the consensus-scored POLR3DP1 profile across patient tissues and cancer cell-line models. POLR3DP1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, POLR3DP1 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, POLR3DP1 RNA expression shows 7,543 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where POLR3DP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3DP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3DP1 survival associations across molecular data types. POLR3DP1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3DP1 RNA expression–survival associations across cancer types. High POLR3DP1 expression shows unfavorable associations in KIRC, KICH, PAAD, HNSC, OV and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for POLR3DP1 RNA expression.
This table summarizes POLR3DP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for POLR3DP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3DP1 shows lower tumor expression in READ and higher tumor expression in BLCA, HNSC, LUAD, STAD and BRCA. The BLCA box plot shows higher POLR3DP1 RNA expression in tumor versus normal tissue (log2 FC = +0.085, t-test p = .002).
This table shows molecular features associated with POLR3DP1 in patient tissues and cancer cell lines. In patient samples, POLR3DP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
